- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07868939
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Hubert Chen, MD
- Phone Number: 8587044660
- Email: clinicaltrials@vikingtherapeutics.com
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85741
- Recruiting
- Viking Clinical Site #2020
-
Contact:
- Phone Number: 520-333-4515
-
-
California
-
Lake Forest, California, United States, 92630
- Recruiting
- Viking Clinical Site #2015
-
Contact:
- Phone Number: 714-550-9990
-
-
Florida
-
Ocoee, Florida, United States, 34761
- Recruiting
- Viking Clinical Site #2059
-
Contact:
- Phone Number: 407-654-2724
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Recruiting
- Viking Clinical Site #2013
-
Contact:
- Phone Number: 404-920-6201
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- Recruiting
- Viking Clinical Site #2001
-
Contact:
- Phone Number: 812-477-2760
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Viking Clinical Site #2046
-
Contact:
- Phone Number: 504-336-2667
-
Valparaiso, Indiana, United States, 46383
- Recruiting
- Viking Clinical Site #2009
-
Contact:
- Phone Number: 219-464-8302
-
-
Minnesota
-
Richfield, Minnesota, United States, 55423
- Recruiting
- Viking Clinical Site #2004
-
Contact:
- Phone Number: 952-922-7000
-
-
Mississippi
-
Jackson, Mississippi, United States, 39206
- Recruiting
- Viking Clinical Site #2029
-
Contact:
- Phone Number: 770-330-4157
-
-
Missouri
-
Springfield, Missouri, United States, 65807
- Recruiting
- Viking Clinical Site #2028
-
Contact:
- Phone Number: 504-338-0917
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87107
- Recruiting
- Viking Clinical Site #2052
-
Contact:
- Phone Number: 505-243-1627
-
-
New York
-
Binghamton, New York, United States, 13905
- Recruiting
- Viking Clinical Site #2039
-
Contact:
- Phone Number: 607-800-5777
-
-
Oregon
-
Medford, Oregon, United States, 97504
- Recruiting
- Viking Clinical Site #2023
-
Contact:
- Phone Number: 541-858-1018
-
-
Rhode Island
-
East Greenwich, Rhode Island, United States, 02818
- Recruiting
- Viking Clinical Site #2002
-
Contact:
- Phone Number: 401-739-9350
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- Recruiting
- Viking Clinical Site #2044
-
Contact:
- Phone Number: 843-432-2477
-
-
Tennessee
-
Hendersonville, Tennessee, United States, 37075
- Recruiting
- Viking Clinical Site #2030
-
Contact:
- Phone Number: 504-339-0917
-
-
Texas
-
Abilene, Texas, United States, 79606
- Recruiting
- Viking Clinical Site #2031
-
Contact:
- Phone Number: 325-400-1150
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Viking Clinical Site #2011
-
Contact:
- Phone Number: 206-536-3030
-
Spokane, Washington, United States, 99218
- Recruiting
- Viking Clinical Site #2042
-
Contact:
- Phone Number: 509-505-6227
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years of age at the time of signing the informed consent.
- Body mass index (BMI) ≥ 27 kg/m2
- Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.
Exclusion Criteria:
-
History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
-
Self-reported body weight change of 5% or more within 3 months of screening
-
Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
-
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
-
Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
-
Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.
-
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
-
Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
-
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
-
History of acute or chronic pancreatitis
-
Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Assignment
Placebo comparator orally once daily |
Placebo comparator administered orally once daily |
|
Experimental: Active Assignment (Dose 1)
VK2735 Dose level 1 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Experimental: Active Assignment (Dose 2)
VK2735 Dose level 2 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Experimental: Active Assignment (Dose 3)
VK2735 Dose level 3 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
Time Frame: 68 weeks
|
To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 |
68 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VK2735-305
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.